FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On February 17, 2025, we reported on the US FDA approval of Penmenvy (GSK), a pentavalent meningococcal vaccine, for individuals aged 10 through 25 years.

The approval

Penmenvy combines antigenic components from GSK's previously approved vaccines, Bexsero (targeting serogroup B) and Menveo (targeting serogroups A, C, W, and Y). The approval was based on positive outcomes from two phase 3 clinical trials (NCT04502693; NCT04707391) involving more than 4800 participants. The vaccine demonstrated a safety profile consistent with GSK’s existing meningococcal vaccines.

The CDC's Advisory Committee on Immunization Practices (ACIP) is scheduled to vote on February 26, 2025, regarding recommendations for Penmenvy's use in adolescents and young adults. If adopted, the decision could further integrate the vaccine into routine immunization programs, simplifying administration and increasing coverage against multiple meningococcal serogroups.

Click here for more details.